Table 1

Patients’ clinical and echocardiographic characteristics and cardiac catheterisation data

Preserved LV function (n=53)Impaired LV function (n=49)p Value
Age (year)67.8±11.468 2±13.50.87
Male, n (%)35 (66)32 (65)0.95
Weight (kg)60.6±12.558.3±12.70.35
Height (cm)160±10159±110.76
Body mass index (kg/m2)23.7±3.6322.9±3.990.77
Systolic blood pressure (mm Hg)126.5±15.4120.5±20.90.095
Diastolic blood pressure (mm Hg)72.9±10.266.7±13.60.010
Diabetes mellitus, n (%)19 (36)25 (51)0.12
Hypertension, n (%)34 (64)25 (51)0.18
Dyslipidaemia, n (%)37 (70)25 (51)0.052
Coronary artery disease, n (%)40 (75)31 (63)0.18
ARBs or ACEIs, n (%)38 (72)28 (57)0.12
β-Blockers, n (%)17 (32)31 (63)0.002
Statins, n (%)26 (49)23 (47)0.83
Calcium channel blockers, n (%)20 (38)17 (35)0.10
Diuretics, n (%)13 (25)33 (67)p<0.001
Blood sugar (mg/dL)108.3±23.0120.4±33.60.035
Glycated haemoglobin HbA1c (%)6.07±1.276.13±1.170.79
Immunoreactive insulin (µU/mL)8.84±8.2211.3±20.30.42
Estimated GFR (mL/min/1.73 m2)69.7±17.454.4±28.70.001
C reactive protein (mg/dL)0.69±2.262.41±4.530.015
GLP-1 (pmol/L)2.72±1.565.71±1.95p<0.001
Brain natriuretic peptide (pg/mL)118±186607±611p<0.001
LVEDVI (mL/m2)81.8±22.2124.1±50.9p<0.001
LVESVI (mL/m2)26.4±12.971.8±43.0p<0.001
Cardiac index (L/min/m2)3.99±1.163.73±1.360.34
LVEF (%)62.0±4.4741.7±10.2p<0.001
  • Data are presented as the number (%) of patients or the mean±SD.

  • ARBs, angiotensin II receptor blockers; E/A, the ratio of mitral inflow E-wave to A-wave velocity; GFR, glomerular filtration rate; GLP-1, glucagon-like peptide-1; LVEDVI, left ventricular end-diastolic volume index; LVEF, left ventricular ejection fraction; LVESVI, left ventricular end-systolic volume index.